Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05358483
Other study ID # STU00215252
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 7, 2021
Est. completion date December 2046

Study information

Verified date April 2022
Source Northwestern University
Contact Emily Jungheim, MD, MSCI
Phone 312-926-6643
Email Emily.Jungheim@nm.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of the PROMISE study is to determine how pre-conception lifestyle factors (e.g., sleep, nutrition, physical activity) affect short- and long-term reproductive outcomes.


Description:

The overall goal of the PROMISE study is to identify strategies to improve health outcomes for women and their children. The proposed study is important and novel as it aims to capture women before they are pregnant. Current research on maternal and child health often focuses on women who are already pregnant. This time period is likely too late to make a meaningful clinical impact on long term maternal and child health outcomes influenced by social and epidemiologic determinants of health as important epigenetic changes are or have already taken place. Examples of tools that will be used to capture social and epidemiologic data include validated surveys for nutrition, physical activity, sleep, and stress. The importance of these tools is that many of the data points captured are modifiable, and therefore if associations are noted between these data points and health outcomes, actionable interventions may be developed and implemented for women who are preconceptional.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 2046
Est. primary completion date December 2046
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 44 Years
Eligibility Inclusion Criteria: - Women ages 18-44 seeking pregnancy at Northwestern Fertility and Reproductive Medicine (FRM) who agree to 1. Be followed for a period for up to 25 years 2. Share information regarding their child's health - No prior IVF cycles Exclusion Criteria: - Women using donor oocytes or gestational carriers - Inability or unwillingness to provide informed consent for any aspects of the study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Northwestern Medicine Fertility and Reproductive Medicine Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Live birth after embryo transfer Live birth after embryo transfer (y/n) ~0-24 months
Secondary Cycle number IVF cycle number ~0-24 months
Secondary AMH Most recent AMH ~0-24 months
Secondary Antral follicle count (AFC) Most recent AFC ~0-24 months
Secondary Diagnosis/reason for ART E.g., male factor, DOR, tubal factor ~0-24 months
Secondary Stimulation type Antagonist, microcode flare, long agonist, minimal stimulation ~0-24 months
Secondary Total gonadotropin dose (IU/L) Total gonadotropin dose ~0-24 months
Secondary Maximum estradiol level (pmol/L) Maximum estradiol level ~0-24 months
Secondary Days of stimulation Total number of days of stimulation ~0-24 months
Secondary Trigger type ~0-24 months
Secondary Sperm source ~0-24 months
Secondary Number follicles >14 mm ~0-24 months
Secondary Cycle cancellation Cycle cancellation (Y/N). If Y, reason for cancellation ~0-24 months
Secondary Number of oocytes retrieved ~0-24 months
Secondary Number of mature oocytes ~0-24 months
Secondary Number of blastocysts ~0-24 months
Secondary Number of embryos transferred ~0-24 months
Secondary Day of embryo transfer ~0-24 months
Secondary Type of embryo transfer Frozen or fresh embryo transfer ~0-24 months
Secondary Frozen embryo transfer protocol ~0-24 months
Secondary Luteal phase support ~0-24 months
Secondary Number of embryos cryopreserved ~0-24 months
Secondary Stage of embryo cryopreservation ~0-24 months
Secondary Grade of embryo transferred ~0-24 months
Secondary PGT ~0-24 months
Secondary PGT indication ~0-24 months
Secondary PGT methodology ~0-24 months
Secondary Endometrial thickness ~0-24 months
Secondary Ovarian hyperstimulation syndrome ~0-24 months
Secondary Clinical outcome ~0-24 months
Secondary Insemination Type ICSI, conventional, split ~0-24 months
Secondary Singleton pregnancy ~12-36 months
Secondary Multiple gestation ~12-36 months
Secondary Asthma ~12-36 months
Secondary Gestational diabetes ~12-36 months
Secondary Insulin ~12-36 months
Secondary Gestational hypertension/pre-eclampsia ~12-36 months
Secondary Abruption ~12-36 months
Secondary Placental disorders Placenta accreta, Placenta previa, Placenta increta, Placenta percreta ~12-36 months
Secondary Intrauterine growth restriction ~12-36 months
Secondary Congenital malformation Cleft palate, genetic defect, limb defect, cardiac defect, other ~12-36 months
Secondary Thyroid disease ~12-36 months
Secondary Heart disease ~12-36 months
Secondary Renal disease ~12-36 months
Secondary Polyhydramnios ~12-36 months
Secondary Lupus ~12-36 months
Secondary Clinical chorioamnionitis ~12-36 months
Secondary Prenatal genetic testing ~12-36 months
Secondary Type of prenatal genetic testing NIPT, CVS, amniocentesis ~12-36 months
Secondary Maternal blood type ~12-36 months
Secondary Preconception COVID vaccination ~12-36 months
Secondary Pregnancy COVID vaccination ~12-36 months
Secondary Predelivery hospitalization ~12-36 months
Secondary Maternal weight at oocyte retrieval Weight (lbs) ~12-36 months
Secondary Maternal height at oocyte retrieval Height (inches) ~12-36 months
Secondary Number of mature oocytes inseminated ~0-24 months
Secondary Number of mature oocytes fertilized (2PN) ~0-24 months
Secondary Maternal weight at embryo transfer ~12-36 months
Secondary Maternal weight at last OB visit ~12-36 months
Secondary Maternal weight at 1 year postpartum ~12-36 months
Secondary Date of delivery ~12-36 months
Secondary Time of delivery ~12-36 months
Secondary Weight at delivery ~12-36 months
Secondary Mode of delivery ~12-36 months
Secondary Preterm birth Birth <37 weeks ~12-36 months
Secondary Spontaneous preterm birth ~12-36 months
Secondary Presentation of spontaneous preterm birth (if applicable) ~12-36 months
Secondary Tocolytic medication during pregnancy ~12-36 months
Secondary Gestational age at delivery ~12-36 months
Secondary Presentation of term birth (if applicable) ~12-36 months
Secondary Magnesium sulfate administered ~12-36 months
Secondary Intrapartum antibiotics ~12-36 months
Secondary Length of hospital stay ~12-36 months
Secondary Head circumference ~12-36 months
Secondary Maternal mortality ~12-36 months
Secondary Infection ~12-36 months
Secondary Anesthetic complication ~12-36 months
Secondary Antepartum hemorrhage ~12-36 months
Secondary Postpartum hemorrhage ~12-36 months
Secondary Blood transfusion ~12-36 months
Secondary Thromboembolism ~12-36 months
Secondary Birthweight ~12-36 months
Secondary Small-for-gestational age ~12-36 months
Secondary Large-for-gestational age ~12-36 months
Secondary 1-min APGAR score ~12-36 months
Secondary 5-min APGAR score ~12-36 months
Secondary Arterial umbilical cord pH ~12-36 months
Secondary Breastfeeding compliance ~12-48 months
Secondary Postpartum weight change ~12-48 months
Secondary General well-being ~12-48 months
Secondary Length of NICU stay ~12-48 months
Secondary Neonatal death <28 days post delivery ~12-48 months
Secondary Breastfeeding ~12-48 months
Secondary Supplemental formula ~12-48 months
Secondary Breastfeeding at 1 year of life ~12-48 months
Secondary Child weight at 1 year of life ~12-48 months
Secondary Child height at 1 year of life ~12-48 months
Secondary NICU admission ~12-48 months
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Completed NCT03177538 - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Phase 4
Completed NCT03638856 - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy N/A
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn NCT04753736 - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC N/A
Completed NCT03349905 - Deferred Versus Fresh Embryo Transfers N/A
Completed NCT05076981 - Progesterone Levels During Ovulation and Luteal Phase
Completed NCT04096027 - Cabergoline Before or After Oocyte Collection for Follicular Resolution Phase 4
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Terminated NCT01933633 - Improved Fertility After Exercise in Overweight/Obese Women N/A
Completed NCT01202656 - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Phase 1/Phase 2
Terminated NCT01202643 - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF Phase 1/Phase 2
Completed NCT01408615 - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation NCT05698550 - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET Phase 3
Not yet recruiting NCT03910582 - Personalized FET in RIF Patients With Displaced Dating N/A
Completed NCT05440019 - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed NCT05130125 - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer
Recruiting NCT06167135 - Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort